Advanced search
Publication Cover
Clinical Toxicology Volume 53, 2015 - Issue 5
Submit an article Journal homepage
549
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Fab fragments of ovine antibody to colchicine enhance its clearance in the rat

Philip W. PeakeDepartment of Nephrology, Prince of Wales Hospital, Sydney, Australia;Prince of Wales Clinical School, University of New South Wales, Sydney, AustraliaCorrespondence[email protected]
,
Timothy J. PiantaDepartment of Nephrology, Prince of Wales Hospital, Sydney, Australia;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
,
Lena SuccarDepartment of Nephrology, Prince of Wales Hospital, Sydney, Australia;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
,
Mangalee FernandoDepartment of Nephrology, Prince of Wales Hospital, Sydney, Australia;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
,
Nicholas A. BuckleyPrince of Wales Clinical School, University of New South Wales, Sydney, Australia
&
Zoltan H. EndreDepartment of Nephrology, Prince of Wales Hospital, Sydney, Australia;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
Pages 427-432 | Received 16 Dec 2014, Accepted 11 Mar 2015, Published online: 10 Apr 2015

References

  • Bhat A, Naguwa SM, Cheema GS, Gershwin ME. Colchicine revisited. Ann N Y Acad Sci 2009; 1173:766–773.
  • Stack J, Ryan J, McCarthy G. Colchicine: new insights to an old drug. Am J Ther 2013; Oct 4. [Epub ahead of print]
  • Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411–419.
  • Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010; 48:407–414.
  • Smith MW, Roberts DM, Ritson SM, Day RO. Death and morbidity from supratherapeutic dosing of colchicine. Med J Aust 2011; 194:612–613.
  • Ben-Chetrit E, Ben-Chetrit E. Colchicine dose reduction in patients with normal liver and kidney function: comment on the article by Terkeltaub et al. Arthritis Rheum 2011; 63:3647–3648; author's reply 3648.
  • Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation.Biochem Pharmacol 1997; 53:111–116.
  • Borron SW, Scherrmann JM, Baud FJ. Markedly altered colchicine kinetics in a fatal intoxication: examination of contributing factors. Hum Exp Toxicol 1996; 15:885–890.
  • Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994; 46:351–354.
  • Solak Y, Atalay H, Biyik Z, Alibasic H, Gaipov A, Guney F, et al. Colchicine toxicity in end-stage renal disease patients: a case-control study. Am J Ther 2014; 21:e189–95.
  • Critchley JA, Critchley LA, Yeung EA, Young RP, Young RJ, Chan TY, Goh VK. Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. Hum Exp Toxicol 1997; 16:229–232.
  • Sabouraud A, Urtizberea M, Grandgeorge M, Gattel P, Makula ME, Scherrmann JM. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. Toxicology 1991; 68:121–132.
  • Sabouraud AE, Urtizberea M, Cano NJ, Grandgeorge M, Rouzioux JM, Scherrmann JM. Colchicine-specific Fab fragments alter colchicine disposition in rabbits. J Pharmacol Exp Ther 1992; 260:1214–1219.
  • Baud FJ, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, et al. Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments. N Engl J Med 1995; 332:642–645.
  • Wiesenfeld PL, Garthoff LH, Sobotka TJ, Suagee JK, Barton CN. Acute oral toxicity of colchicine in rats: effects of gender, vehicle matrix and pre-exposure to lipopolysaccharide. J Appl Toxicol 2007; 27:421–433.
  • Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004; 27:1115–1133.
  • Rochdi M, Sabouraud A, Baud FJ, Bismuth C, Scherrmann JM. Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. Hum Exp Toxicol 1992; 11:510–516.
  • Sabouraud A, Redureau M, Gires P, Martinet M, Scherrmann JM. Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine. Drug Metab Dispos 1993; 21:997–1002.
  • Banerjee A, Luduena RF. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J Biol Chem 1992; 267:13335–13339.
  • Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30: 527–533.
  • Moran RJ, Struthers AD, Hewick DS. Digoxin-specific Fab fragments impair renal function in the rat. J Pharm Pharmacol 1994; 46: 854–856.
  • Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton) 2010; 15:419–428.
  • Munir MU, Khan DA, Khan FA, Shahab Naqvi SM. Rapid detection of acute kidney injury by urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass surgery. J Coll Physicians Surg Pak. 2013; 23:103–106.
  • Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17:216–222.
  • Lim AI, Tang SC, Lai KN, Leung JC. Kidney injury molecule-1: more than just an injury marker of tubular epithelial cells? J Cell Physiol 2013; 228:917–924.
  • Advenier E, Mouajjah S, Bazin-Redureau M, Launay JM, Scherrmann JM. Renal tolerance of digoxin-specific Fab fragments in the rat. Toxicology 1998; 126:223–229.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.